LENZ

LENZ Therapeutics, Inc. - 10-Q Summary (Q3 2025)

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2025. LENZ Therapeutics, Inc. is a commercial pharmaceutical company focused on the development and commercialization of VIZZ™ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia. The FDA approved VIZZ on July 31, 2025, and the company commercially launched the product in the U.S. in August 2025. The company is classified as an emerging growth company and a smaller reporting company.

Key Financial Metrics

Note: Revenue consists entirely of license revenue. There were no product sales recorded as of September 30, 2025.

Material Changes vs. Prior Period

• Revenue Generation: The company recognized $12.5 million in license revenue for Q3 2025, compared to zero in Q3 2024. This was driven by a $5.0 million upfront payment from the Laboratoires Théa license (Canada) and two regulatory milestones ($5.0 million each) under the CORXEL license (Greater China) triggered by NDA submission and FDA approval.
• Expense Surge: Selling, general, and administrative (SG&A) expenses increased 325% year-over-year to $27.6 million in Q3 2025. This increase is attributed to the hiring of an 88-territory sales force, commercial marketing infrastructure, and the reclassification of certain regulatory and quality assurance costs from R&D to SG&A following FDA approval.
• R&D Decline: Research and development expenses decreased 41% year-over-year to $3.8 million in Q3 2025, primarily due to the completion of Phase 3 trials and the shift of post-approval costs to SG&A.
• Liquidity: Cash and marketable securities decreased slightly to $202.2 million from $209.0 million at year-end 2024, despite net operating cash outflows, due to proceeds from an "at-the-market" offering ($26.1 million net) and interest income.

Guidance, Outlook, and Risks

Outlook: Management believes existing cash, cash equivalents, and marketable securities ($202.2 million) are sufficient to fund operations for at least the next 12 months and support the company to positive operating cash flow. The company expects to continue incurring significant expenses related to the commercialization of VIZZ, including sales, marketing, and manufacturing costs.

Recent Developments:

• Commercial product shipments via e-pharmacy partner initiated in October 2025.
• Anticipated broad availability in retail pharmacies in mid-Q4 2025.
• In October 2025, the company utilized the remaining capacity of its Sales Agreement, selling 2.7 million shares at a weighted-average price of $45.79.

Risks and Contingencies:

• Market Acceptance: Success depends entirely on VIZZ. The company faces competition from Vuity (AbbVie), Qlosi (Orasis), and generic versions of Vuity. Market acceptance may be hindered if patients or eye care professionals perceive VIZZ as less effective or durable than competitors.
• Manufacturing Reliance: The company relies entirely on third-party manufacturers for commercial supply. Disruptions could delay or prevent sales.
• Regulatory & Legal: Ongoing regulatory oversight, potential product liability claims, and the need to maintain patent protection (patents expire 2044, NCE exclusivity 2030) are critical risks.

Investor Verification Checklist

• Commercial Execution: Verify the timeline for broad retail pharmacy availability and initial prescription volume data post-launch.
• Licensing Milestones: Confirm the status of regulatory submissions in Greater China (NDA) and Southeast Asia to assess future milestone revenue potential.
• Capital Efficiency: Monitor the burn rate relative to the $202.2 million cash position to validate the 12-month runway assertion.
• Competitive Landscape: Assess market share data and refill rates for VIZZ compared to Vuity and Qlosi.
• Supply Chain: Review capacity agreements with third-party manufacturers to ensure they can meet potential demand spikes.